Program
Artesunate
Also written as “Artesunate + Amodiaquine”, “Artesunate ointment” and “Artesunate vaginal insert”.
Its studies are mostly in Malaria · Papillomavirus Infections · Malaria, Falciparum · Cytomegalovirus Infections · Vulvar Diseases, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 60 open or running | phase 4since Mar 8, 2007 | Apr 18, 2006 | none ahead |
| Frantz Viral Therapeutics | 44 open or running | phase 2since Sep 19, 2019 | Sep 19, 2019 | Dec 2026phase 2 · NCT06075264 |
| Metanoic Health | 22 open or running | phase 2since Jul 7, 2025 | Jul 7, 2025 | Jun 30, 2027phase 2 · NCT07095478 |
| Shin Poong Pharmaceutical | 20 open or running | phase 2since Sep 13, 2018 | Sep 13, 2018 | none ahead |
| Amivas | 11 open or running | phase 2since Feb 25, 2025 | Feb 25, 2025 | May 31, 2028phase 2 · NCT06853184 |
| Pfizer | 10 open or running | phase 1since May 4, 2009 | May 4, 2009 | none ahead |
| Teva Pharmaceutical Industries | 10 open or running | phase 4since Sep 10, 2009 | Sep 10, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Apr 18, 2006.
- Oct 10, 2006Phase 1 study in MalariaSanofi · NCT00386503 · 22 enrolled · France
- Mar 8, 20072 phase 4 studies in MalariaSanofi · NCT00445796, NCT00452907
- May 4, 2009Pfizer's first study: phase 1 study in Malaria, FalciparumNew to PfizerPfizer · NCT00894374 · 40 enrolled · Singapore
- Sep 10, 2009Teva Pharmaceutical Industries's first study: phase 4 study in MalariaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00978172 · 220 enrolled · Cameroon
- Dec 1, 2009Phase 4 study in MalariaSanofi · NCT01023399 · 580 enrolled · Côte D'Ivoire
- Jun 20, 2011Phase 3 study in MalariaSanofi · NCT01378286 · 380 enrolled · Brazil
- Sep 13, 2018Shin Poong Pharmaceutical's first study: phase 2 study in Malaria, FalciparumNew to Shin Poong PharmaceuticalShin Poong Pharmaceutical · NCT03814616 · 300 enrolled · Gambia, Zambia
- Sep 19, 2019Frantz Viral Therapeutics's first study: phase 2 study in Papillomavirus InfectionsNew to Frantz Viral TherapeuticsFrantz Viral Therapeutics · NCT04098744 · 78 planned · United States
- Aug 26, 2020Phase 2 study in COVID-19Shin Poong Pharmaceutical · NCT04532931 · 192 enrolled · South Africa
- Sep 22, 2022Phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862 · 17 enrolled · United States
- Oct 4, 2023Phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264 · 27 planned · United States
- Jan 3, 2024Phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564 · 48 planned · United States
- Feb 25, 2025Amivas's first study: phase 2 study in Cytomegalovirus InfectionsNew to AmivasAmivas · NCT06853184 · 90 planned · United States, Australia
- Jul 7, 2025Metanoic Health's first studies: 2 phase 2 studiesNew to Metanoic HealthMetanoic Health · NCT07095478, NCT07095309
Ahead
- Dec 2026Primary completion: phase 2 study in Vulvar DiseasesFrantz Viral Therapeutics · NCT06075264
- Dec 28, 2026Primary completion: phase 2 study in Papillomavirus InfectionsFrantz Viral Therapeutics · NCT05555862
- Dec 31, 2026Primary completion: phase 2 study in Anal High-grade Squamous Intraepithelial LesionFrantz Viral Therapeutics · NCT06206564
- Jun 30, 2027Primary completion: phase 2 study in CIN 2/3Metanoic Health · NCT07095478
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07095478CIN 2/3 · Malaysia | 2 | Not yet recruiting | Metanoic Health | Jun 30, 2027 | 28 |
| NCT07095309Intestinal Neoplasms · Malaysia | 2 | Not yet recruiting | Metanoic Health | Aug 30, 2032 | 120 |
| NCT06853184Cytomegalovirus Infections · United States, Australia | 2 | Recruiting | Amivas | May 31, 2028 | 90 |
| NCT06206564Anal High-grade Squamous Intraepithelial Lesion · United States | 2 | Recruiting | Frantz Viral Therapeutics | Dec 31, 2026 | 48 |
| NCT06075264Vulvar Diseases · United States | 2 | Recruiting | Frantz Viral Therapeutics | Dec 2026 | 27 |
| NCT05555862Papillomavirus Infections · United States | 2 | Active, not recruiting | Frantz Viral Therapeutics | Dec 28, 2026 | 17 |
| NCT04532931COVID-19 · South Africa | 2 | Completed | Shin Poong Pharmaceutical | Aug 5, 2021 | 192 |
| NCT04098744Papillomavirus Infections · United States | 2 | Recruiting | Frantz Viral Therapeutics | Jul 31, 2026 | 78 |
| NCT03814616Malaria, Falciparum · Gambia, Zambia | 2 | UNKNOWN | Shin Poong Pharmaceutical | Oct 2019 | 300 |
| NCT01378286Malaria · Brazil | 3 | Completed | Sanofi | Jun 2013 | 380 |
| NCT01023399Malaria · Côte D'Ivoire | 4 | Completed | Sanofi | Oct 2013 | 580 |
| NCT00978172Malaria · Cameroon | 4 | Completed | Teva Pharmaceutical Industries | 220 | |
| NCT00894374Malaria, Falciparum · Singapore | 1 | Completed | Pfizer | Aug 2009 | 40 |
| NCT00452907Malaria · Mali | 4 | Completed | Sanofi | Jun 2007 | 780 |
| NCT00445796Malaria · Cameroon, Senegal | 4 | Completed | Sanofi | 300 | |
| NCT00386503Malaria · France | 1 | Completed | Sanofi | Dec 2006 | 22 |
| NCT00316329Malaria · Cameroon, Madagascar, Mali and more | 3 | Completed | Sanofi | 1,032 |
How it is read
Names in the registry
- “Artesunate”, 6 entries
- “Artesunate + Amodiaquine”, 3 entries
- “Artesunate ointment”, 2 entries
- “Artesunate vaginal insert”, 1 entry
- “Artesunate-amodiaquine”, 1 entry
Conditions, from the studies’ own filings
- Malaria, 7 studies
- Papillomavirus Infections, 3 studies
- Malaria, Falciparum, 2 studies
- Cytomegalovirus Infections, 1 study
- Vulvar Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.